Chronic obstructive pulmonary disease

Respiratory Genetics

Volumn , Issue , 2005, Pages 253-296

  Hersh, Craig P ^a   Demeo, Dawn L ^a   Silverman, Edwin K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84988895356     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b13341-66     Document Type: Chapter

References (540)

1. Pauwels RA, Buist AS, Calverley PM et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-76.
2. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981; 123: 659-64.
3. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med 1999; 159: 179-87.
4. Chen Y. Genetics and pulmonary medicine. 10: Genetic epidemiology of pulmonary function. Thorax 1999; 54: 818-24.
5. Hubert HB, Fabsitz RR, Feinleib M, Gwinn C. Genetic and environmental influences on pulmonary function in adult twins. Am Rev Respir Dis 1982; 125: 409-15.
6. Redline S, Tishler PV, Lewitter FI et al. Assessment of genetic and nongenetic influences on pulmonary function. A twin study. Am Rev Respir Dis 1987; 135: 217-22.
7. Man SF, Zamel N. Genetic influence on normal variability of maximum expiratory flow-volume curves. J Appl Physiol 1976; 41: 874-7.
8. Kawakami Y, Shida A, Yamamoto H, Yoshikawa T. Pattern of genetic influence on pulmonary function. Chest 1985; 87: 507-11.
9. Ghio AJ, Crapo RO, Elliott CG et al. Heritability estimates of pulmonary function. Chest 1989; 96: 743-6.
10. Webster PM, Lorimer EG, Man SF et al. Pulmonary function in identical twins: comparison of nonsmokers and smokers. Am Rev Respir Dis 1979; 119: 223-8.
11. Hankins D, Drage C, Zamel N, Kronenberg R. Pulmonary function in identical twins raised apart. Am Rev Respir Dis 1982; 125: 119-21.
12. Tishler PV, Carey VJ, Reed T, Fabsitz RR. The role of genotype in determining the effects of cigarette smoking on pulmonary function. Genet Epidemiol 2002; 22: 272-82.
13. Higgins M, Keller J. Familial occurrence of chronic respiratory disease and familial resemblance in ventilatory capacity. J Chronic Dis 1975; 28: 239-51.
14. Tager IB, Rosner B, Tishler PV et al. Household aggregation of pulmonary function and chronic bronchitis. Am Rev Respir Dis 1976; 114: 485-92.
15. Perusse L, Leblanc C, Tremblay A et al. Familial aggregation in physical fitness, coronary heart disease risk factors, and pulmonary function measurements. Prev Med 1987; 16: 607-15.
16. Redline S, Tishler PV, Rosner B et al. Genotypic and phenotypic similarities in pulmonary function among family members of adult monozygotic and dizygotic twins. Am J Epidemiol 1989; 129: 827-36.
17. Kauffmann F, Tager IB, Munoz A, Speizer FE. Familial factors related to lung function in children aged 6-10 years. Results from the PAARC epidemiologic study. Am J Epidemiol 1989; 129: 1289-99.
18. Schilling RS, Letai AD, Hui SL et al. Lung function, respiratory disease, and smoking in families. Am J Epidemiol 1977; 106: 274-83.
19. Lebowitz MD, Knudson RJ, Burrows B. Family aggregation of pulmonary function measurements. Am Rev Respir Dis 1984; 129: 8-11.
20. Cotch MF, Beaty TH, Munoz A, Cohen BH. Estimating familial aggregation while adjusting for covariates. Application to pulmonary function data from black and white sibships. Ann Epidemiol 1992; 2: 317-24.
21. Xu X, Yang J, Chen C et al. Familial aggregation of pulmonary function in a rural Chinese community. Am J Respir Crit Care Med 1999; 160: 1928-33.
22. McClearn GE, Svartengren M, Pedersen NL et al. Genetic and environmental influences on pulmonary function in aging Swedish twins. J Gerontol 1994; 49: 264-8.
23. Lewitter FI, Tager IB, McGue M et al. Genetic and environmental determinants of level of pulmonary function. Am J Epidemiol 1984; 120: 518-30.
24. Devor EJ, Crawford MH. Family resemblance for normal pulmonary function. Ann Hum Biol 1984; 11: 439-48.
25. Cotch MF, Beaty TH, Cohen BH. Path analysis of familial resemblance of pulmonary function and cigarette smoking. Am Rev Respir Dis 1990; 142: 1337-43.
26. Coultas DB, Hanis CL, Howard CA et al. Heritability of ventilatory function in smoking and nonsmoking New Mexico Hispanics. Am Rev Respir Dis 1991; 144: 770-5.
27. Province MA. Linkage and association with structural relationships. In: Rao DC, Province MA (eds) Genetic dissection of complex traits. Boston: Academic Press, 2001: 183-90.
28. Astemborski JA, Beaty TH, Cohen BH. Variance components analysis of forced expiration in families. Am J Med Genet 1985; 21: 741-53.
29. Beaty TH, Liang KY, Seerey S, Cohen BH. Robust inference for variance components models in families ascertained through probands: II. Analysis of spirometric measures. Genet Epidemiol 1987; 4: 211-21.
30. Palmer LJ, Knuiman MW, Divitini ML et al. Familial aggregation and heritability of adult lung function: results from the Busselton Health Study. Eur Respir J 2001; 17: 696-702.
31. Rybicki BA, Beaty TH, Cohen BH. Major genetic mechanisms in pulmonary function. J Clin Epidemiol 1990; 43: 667-75.
32. Chen Y, Horne SL, Rennie DC, Dosman JA. Segregation analysis of two lung function indices in a random sample of young families: the Humboldt Family Study. Genet Epidemiol 1996; 13: 35-47.
33. Givelber RJ, Couropmitree NN, Gottlieb DJ et al. Segregation analysis of pulmonary function among families in the Framingham Study. Am J Respir Crit Care Med 1998; 157: 1445-51.
34. Holberg CJ, Morgan WJ, Wright AL, Martinez FD. Differences in familial segregation of FEV1 between asthmatic and nonasthmatic families. Role of a maternal component. Am J Respir Crit Care Med 1998; 158: 162-9.
35. Kurzius-Spencer M, Holberg CJ, Martinez FD, Sherrill DL. Familial correlation and segregation analysis of forced expiratory volume in one second (FEV1), with and without smoking adjustments, in a Tucson population. Ann Hum Biol 2001; 28: 222-34.
36. Wilk JB, Djousse L, Arnett DK et al. Evidence for major genes influencing pulmonary function in the NHLBI family heart study. Genet Epidemiol 2000; 19: 81-94.
37. Chen Y, Rennie DC, Lockinger LA, Dosman JA. Major genetic effect on forced vital capacity: the Humboldt Family Study. Genet Epidemiol 1997; 14: 63-76.
38. Sandford AJ, Chagani T, Weir TD et al. Susceptibility genes for rapid decline of lung function in the Lung Health Study. Am J Respir Crit Care Med 2001; 163: 469-73.
39. Silva GE, Sherrill DL, Guerra S, Barbee RA. A longitudinal study of alpha 1-antitrypsin phenotypes and decline in FEV1 in a community population. Chest 2003; 123: 1435-40.
40. Kurzius-Spencer M, Sherrill DL, Holberg CJ et al. Familial correlation in the decline of forced expiratory volume in one second. Am J Respir Crit Care Med 2001; 164: 1261-5.
41. Gottlieb DJ, Wilk JB, Harmon M et al. Heritability of longitudinal change in lung function. The Framingham study. Am J Respir Crit Care Med 2001; 164: 1655-9.
42. Chen Y, Dosman JA, Rennie DC, Lockinger LA. Major genetic effects on airway-parenchymal dysanapsis of the lung: the Humboldt family study. Genet Epidemiol 1999; 16: 95-110.
43. Joost O, Wilk JB, Cupples LA et al. Genetic loci influencing lung function: a genome-wide scan in the Framingham Study. Am J Respir Crit Care Med 2002; 165: 795-9.
44. Wilk JB, DeStefano AL, Joost O et al. Linkage and association with pulmonary function measures on chromosome 6q27 in the Framingham Heart Study. Hum Mol Genet 2003; 12: 2745-51.
45. Wilk JB, DeStefano AL, Arnett DK et al. A genome-wide scan of pulmonary function measures in the National Heart, Lung, and Blood Institute Family Heart Study. Am J Respir Crit Care Med 2003; 167: 1528-33.
46. Dausset J, Cann H, Cohen D et al. Centre d’etude du polymorphisme humain (CEPH): collaborative genetic mapping of the human genome. Genomics 1990; 6: 575-7.
47. Malhotra A, Peiffer AP, Ryujin DT et al. Further evidence for the role of genes on chromosome 2 and chromosome 5 in the inheritance of pulmonary function. Am J Respir Crit Care Med 2003; 168: 556-61.
48. Mathias RA, Freidhoff LR, Blumenthal MN et al. Genome-wide linkage analyses of total serum IgE using variance components analysis in asthmatic families. Genet Epidemiol 2001; 20: 340-55.
49. Altmuller J, Palmer LJ, Fischer G et al. Genomewide scans of complex human diseases: true linkage is hard to find. Am J Hum Genet 2001; 69: 936-50.
50. Mannino DM, Homa DM, Akinbami LJ et al. Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. MMWR Surveill Summ 2002; 51: 1-16.
51. Morbidity and mortality: 2002 chart book on cardiovascular, lung, and blood diseases. Bethesda, MD: National Institutes of Health: National Heart, Lung, and Blood Institute, 2002.
52. Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest 2000; 117: 5S-9S.
53. Fabbri LM, Hurd SS. Global strategy for the diagnosis, management and prevention of COPD: 2003 update. Eur Respir J 2003; 22: 1-2.
54. Vestbo J, Lange P. Can GOLD Stage 0 provide information of prognostic value in chronic obstructive pulmonary disease? Am J Respir Crit Care Med 2002; 166: 329-32.
55. Burrows B, Knudson RJ, Cline MG, Lebowitz MD. Quantitative relationships between cigarette smoking and ventilatory function. Am Rev Respir Dis 1977; 115: 195-205.
56. Silverman EK, Speizer FE. Risk factors for the development of chronic obstructive pulmonary disease. Med Clin North Am 1996; 80: 501-22.
57. Orie NGM, Sluiter HJ, DeVries K et al. The host factor in bronchitis. In: Orie NGM, Sluiter HJ (eds). Bronchitis. Assen: Royal von Gorcum, 1961.
58. Tager IB, Segal MR, Speizer FE, Weiss ST. The natural history of forced expiratory volumes. Effect of cigarette smoking and respiratory symptoms. Am Rev Respir Dis 1988; 138: 837-49.
59. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am J Respir Crit Care Med 1995; 152: S77-121.
60. Siafakas NM, Vermeire P, Pride NB et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995; 8: 1398-420.
61. BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS. Thorax 1997; 52 (Suppl. 5): S1-28.
62. Chronic bronchitis, asthma and pulmonary emphysema. A statement by the Committee on Diagnostic Standards for Nontuberculous Respiratory Diseases. Am Rev Respir Dis 1962; 85: 762.
63. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996; 153: 1530-5.
64. American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique - 1995 update. Am J Respir Crit Care Med 1995; 152: 2185-98.
65. Morrison NJ, Abboud RT, Ramadan F et al. Comparison of single breath carbon monoxide diffusing capacity and pressure-volume curves in detecting emphysema. Am Rev Respir Dis 1989; 139: 1179-87.
66. Muller NL, Coxson H. Chronic obstructive pulmonary disease. 4: imaging the lungs in patients with chronic obstructive pulmonary disease. Thorax 2002; 57: 982-5.
67. Madani A, Keyzer C, Gevenois PA. Quantitative computed tomography assessment of lung structure and function in pulmonary emphysema. Eur Respir J 2001; 18: 720-30.
68. Newell JD Jr. CT of emphysema. Radiol Clin North Am 2002; 40: 31-42.
69. Rationale and design of the National Emphysema Treatment Trial: a prospective randomized trial of lung volume reduction surgery. The National Emphysema Treatment Trial Research Group. Chest 1999; 116: 1750-61.
70. Fishman A, Martinez F, Naunheim K et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. New Engl J Med 2003; 348: 2059-73.
71. Dirksen A, Dijkman JH, Madsen F et al. A randomized clinical trial of alpha 1-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999; 160: 1468-72.
72. Kauczor HU, Chen XJ, van Beek EJ, Schreiber WG. Pulmonary ventilation imaged by magnetic resonance: at the doorstep of clinical application. Eur Respir J 2001; 17: 1008-23.
73. de Lange EE, Mugler JP 3rd, Brookeman JR et al. Lung air spaces: MR imaging evaluation with hyperpolarized 3He gas. Radiology 1999; 210: 851-7.
74. van Beurden WJ, Dekhuijzen PN, Smeenk FW. Exhaled biomarkers in COPD: their potential role in diagnosis, treatment and prognosis. Monaldi Arch Chest Dis 2002; 57: 258-67.
75. Garey KW, Neuhauser MM, Robbins RA et al. Markers of inflammation in exhaled breath condensate of young healthy smokers. Chest 2004; 125: 22-6.
76. Paredi P, Kharitonov SA, Barnes PJ. Analysis of expired air for oxidation products. Am J Respir Crit Care Med 2002; 166: S31-7.
77. Jones HA, Marino PS, Shakur BH, Morrell NW. In vivo assessment of lung inflammatory cell activity in patients with COPD and asthma. Eur Respir J 2003; 21: 567-73.
78. Fletcher CM, Peto R, Tinker CM, Speizer FE. The natural history of chronic bronchitis and emphysema. Oxford: Oxford University Press, 1976.
79. Xu X, Dockery DW, Ware JH et al. Effects of cigarette smoking on rate of loss of pulmonary function in adults: a longitudinal assessment. Am Rev Respir Dis 1992; 146: 1345-8.
80. Stone PJ, Bryan-Rhadfi J, Lucey EC et al. Measurement of urinary desmosine by isotope dilution and high performance liquid chromatography. Correlation between elastase-induced air-space enlargement in the hamster and elevation of urinary desmosine. Am Rev Respir Dis 1991; 144: 284-90.
81. Stone PJ, Gottlieb DJ, O’Connor GT et al. Elastin and collagen degradation products in urine of smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 151: 952-9.
82. Gottlieb DJ, Stone PJ, Sparrow D et al. Urinary desmosine excretion in smokers with and without rapid decline of lung function: the Normative Aging Study. Am J Respir Crit Care Med 1996; 154: 1290-5.
83. Fiorenza D, Viglio S, Lupi A et al. Urinary desmosine excretion in acute exacerbations of COPD: a preliminary report. Respir Med 2002; 96: 110-4.
84. Cantor JO, Shteyngart B. How a test for elastic fiber breakdown products in sputum could speed development of a treatment for pulmonary emphysema. Med Sci Monit 2004; 10: RA1-4.
85. Ma S, Lieberman S, Turino GM, Lin YY. The detection and quantitation of free desmosine and isodesmosine in human urine and their peptide-bound forms in sputum. Proc Natl Acad Sci USA 2003; 100: 12941-3.
86. US Department of Health and Human Services. The health consequences of smoking: a report of the surgeon general. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2004.
87. Gold DR, Wang X, Wypij D et al. Effects of cigarette smoking on lung function in adolescent boys and girls. New Engl J Med 1996; 335: 931-7.
88. Sherrill DL, Lebowitz MD, Knudson RJ, Burrows B. Smoking and symptom effects on the curves of lung function growth and decline. Am Rev Respir Dis 1991; 144: 17-22.
89. Stick SM, Burton PR, Gurrin L et al. Effects of maternal smoking during pregnancy and a family history of asthma on respiratory function in newborn infants. Lancet 1996; 348: 1060-4.
90. Lodrup Carlsen KC, Jaakkola JJ, Nafstad P, Carlsen KH. In utero exposure to cigarette smoking influences lung function at birth. Eur Respir J 1997; 10: 1774-9.
91. Hoo AF, Henschen M, Dezateux C et al. Respiratory function among preterm infants whose mothers smoked during pregnancy. Am J Respir Crit Care Med 1998; 158: 700-5.
92. Guerassimov A, Hoshino Y, Takubo Y et al. The development of emphysema in cigarette smoke-exposed mice is strain dependent. Am J Respir Crit Care Med 2004; 170: 974-80.
93. Savov JD, Whitehead GS, Wang J et al. Ozone-induced acute pulmonary injury in inbred mouse strains. Am J Respir Cell Mol Biol 2004; 31: 69-77.
94. Kiraz K, Kart L, Demir R et al. Chronic pulmonary disease in rural women exposed to biomass fumes. Clin Invest Med 2003; 26: 243-8.
95. Amoli K. Bronchopulmonary disease in Iranian housewives chronically exposed to indoor smoke. Eur Respir J 1998; 11: 659-63.
96. Perez-Padilla R, Regalado J, Vedal S et al. Exposure to biomass smoke and chronic airway disease in Mexican women. A case-control study. Am J Respir Crit Care Med 1996; 154: 701-6.
97. Dennis RJ, Maldonado D, Norman S et al. Woodsmoke exposure and risk for obstructive airways disease among women. Chest 1996; 109: 115-9.
98. Dossing M, Khan J, al-Rabiah F. Risk factors for chronic obstructive lung disease in Saudi Arabia. Respir Med 1994; 88: 519-22.
99. Behera D, Jindal SK. Respiratory symptoms in Indian women using domestic cooking fuels. Chest 1991; 100: 385-8.
100. Samet JM, Marbury MC, Spengler JD. Health effects and sources of indoor air pollution. Part I. Am Rev Respir Dis 1987; 136: 1486-508.
101. Samet JM, Marbury MC, Spengler JD. Respiratory effects of indoor air pollution. J Allergy Clin Immunol 1987; 79: 685-700.
102. Heppleston AG. Prevalence and pathogenesis of pneumoconiosis in coal workers. Environ Health Perspect 1988; 78: 159-70.
103. Armstrong BG, Kazantzis G. The mortality of cadmium workers. Lancet 1983; 1: 1425-7.
104. Davison AG, Fayers PM, Taylor AJ et al. Cadmium fume inhalation and emphysema. Lancet 1988; 1: 663-7.
105. Snider GL, Hayes JA, Korthy AL, Lewis GP. Centrilobular emphysema experimentally induced by cadmium chloride aerosol. Am Rev Respir Dis 1973; 108: 40-8.
106. Paschal DC, Burt V, Caudill SP et al. Exposure of the US population aged 6 years and older to cadmium: 1988-1994. Arch Environ Contam Toxicol 2000; 38: 377-83.
107. Elinder CG, Friberg L, Lind B, Jawaid M. Lead and cadmium levels in blood samples from the general population of Sweden. Environ Res 1983; 30: 233-53.
108. Watanabe T, Koizumi A, Fujita H et al. Cadmium levels in the blood of inhabitants in nonpolluted areas in Japan with special references to aging and smoking. Environ Res 1983; 31: 472-83.
109. Mannino DM, Holguin F, Greves HM et al. Urinary cadmium levels predict lower lung function in current and former smokers: data from the Third National Health and Nutrition Examination Survey. Thorax 2004; 59: 194-8.
110. Bjorkman L, Vahter M, Pedersen NL. Both the environment and genes are important for concentrations of cadmium and lead in blood. Environ Health Perspect 2000; 108: 719-22.
111. Takeda K, Ishizawa S, Sato M et al. Identification of a cisacting element that is responsible for cadmium-mediated induction of the human heme oxygenase gene. J Biol Chem 1994; 269: 22858-67.
112. Alam J, Shibahara S, Smith A. Transcriptional activation of the heme oxygenase gene by heme and cadmium in mouse hepatoma cells. J Biol Chem 1989; 264: 6371-5.
113. Yamada N, Yamaya M, Okinaga S et al. Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. Am J Hum Genet 2000; 66: 187-95.
114. Diaz PT, Clanton TL, Pacht ER. Emphysema-like pulmonary disease associated with human immunodeficiency virus infection. Ann Intern Med 1992; 116: 124-8.
115. Wewers MD, Diaz PT, Wewers ME et al. Cigarette smoking in HIV infection induces a suppressive inflammatory environment in the lung. Am J Respir Crit Care Med 1998; 158: 1543-9.
116. Weinberg JB, Matthews TJ, Cullen BR, Malim MH. Productive human immunodeficiency virus type 1 (HIV-1) infection of nonproliferating human monocytes. J Exp Med 1991; 174: 1477-82.
117. Fagerhol MK, Laurell CB. The Pi system-inherited variants of serum alpha 1-antitrypsin. Prog Med Genet 1970; 7: 96-111.
118. Fagerhol MK. Serum Pi types in Norwegians. Acta Pathol Microbiol Scand 1967; 70: 421-8.
119. Hjalmarsson K. Distribution of alpha-1-antitrypsin phenotypes in Sweden. Hum Hered 1988; 38: 27-30.
120. Arnaud P, Koistinen J, Wilson GB, Fudenberg HH. Alpha 1-antitrypsin (Pi) phenotypes in a Finnish population. Scand J Clin Lab Invest 1977; 37: 339-43.
121. Arnaud P, Galbraith RM, Faulk WP, Black C. Pi phenotypes of alpha1-antitrypsin in southern England: identification of M subtypes and implications for genetic studies. Clin Genet 1979; 15: 406-10.
122. Thymann M. Distribution of alpha-1-antitrypsin (Pi) phenotypes in Denmark determined by separator isoelectric focusing in agarose gel. Hum Hered 1986; 36: 19-23.
123. Hoffmann JJ, van den Broek WG. Distribution of alpha-1-antitrypsin phenotypes in two Dutch population groups. Hum Genet 1976; 32: 43-8.
124. Sesboue R, Charlionet R, Vercaigne D et al. Genetic variants of serum alpha-1-antitrypsin (Pi types) in Bretons. Hum Hered 1978; 28: 280-4.
125. Luisetti M, Seersholm N. Alpha1-antitrypsin deficiency. 1: epidemiology of alpha1-antitrypsin deficiency. Thorax 2004; 59: 164-9.
126. American Thoracic Society/European Respiratory Society Statement: Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168: 818-900.
127. Crystal RG. Alpha 1-antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy. J Clin Invest 1990; 85: 1343-52.
128. Ogushi F, Fells GA, Hubbard RC et al. Z-type alpha 1-antitrypsin is less competent than M1-type alpha 1-antitrypsin as an inhibitor of neutrophil elastase. J Clin Invest 1987; 80: 1366-74.
129. Lomas DA, Evans DL, Finch JT, Carrell RW. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature 1992; 357: 605-7.
130. Lee JH, Brantly M. Molecular mechanisms of alpha 1-antitrypsin null alleles. Respir Med 2000; 94 (Suppl. C): S7-11.
131. Sifers RN, Brashears-Macatee S, Kidd VJ et al. A frameshift mutation results in a truncated alpha 1-antitrypsin that is retained within the rough endoplasmic reticulum. J Biol Chem 1988; 263: 7330-5.
132. Nukiwa T, Takahashi H, Brantly M et al. alpha 1-Antitrypsin nullGranite Falls, a nonexpressing alpha 1-antitrypsin gene associated with a frameshift to stop mutation in a coding exon. J Biol Chem 1987; 262: 11999-2004.
133. Takahashi H, Nukiwa T, Satoh K et al. Characterization of the gene and protein of the alpha 1-antitrypsin ‘deficiency’ allele Mprocida. J Biol Chem 1988; 263: 15528-34.
134. Hofker MH, Nukiwa T, van Paassen HM et al. A Pro-Leu substitution in codon 369 of the alpha-1-antitrypsin deficiency variant PI MHeerlen. Hum Genet 1989; 81: 264-8.
135. Kalsheker N, Hayes K, Weidinger S, Graham A. What is Pi (proteinase inhibitor) null or PiQO?: a problem highlighted by the alpha 1-antitrypsin Mheerlen mutation. J Med Genet 1992; 29: 27-9.
136. Curiel DT, Holmes MD, Okayama H et al. Molecular basis of the liver and lung disease associated with the alpha 1-antitrypsin deficiency allele Mmalton. J Biol Chem 1989; 264: 13938-45.
137. Seyama K, Nukiwa T, Takabe K et al. Siiyama serine 53 (TCC) to phenylalanine 53 (TTC). A new alpha 1-antitrypsin-deficient variant with mutation on a predicted conserved residue of the serpin backbone. J Biol Chem 1991; 266: 12627-32.
138. Seyama K, Nukiwa T, Souma S et al. Alpha 1-antitrypsindeficient variant Siiyama (Ser53[TCC] to Phe53[TTC]) is prevalent in Japa. Status of alpha 1-antitrypsin deficiency in Japan. Am J Respir Crit Care Med 1995; 152: 2119-26.
139. Cox DW, Levison H. Emphysema of early onset associated with a complete deficiency of alpha-1-antitrypsin (null homozygotes). Am Rev Respir Dis 1988; 137: 371-5.
140. Garver RI Jr, Mornex JF, Nukiwa T et al. Alpha 1-antitrypsin deficiency and emphysema caused by homozygous inheritance of non-expressing alpha 1-antitrypsin genes. New Engl J Med 1986; 314: 762-6.
141. Martin NG, Clark P, Ofulue AF et al. Does the PI polymorphism alone control alpha-1-antitrypsin expression? Am J Hum Genet 1987; 40: 267-77.
142. Silverman EK, Province MA, Campbell EJ et al. Family study of alpha 1-antitrypsin deficiency: effects of cigarette smoking, measured genotype, and their interaction on pulmonary function and biochemical traits. Genet Epidemiol 1992; 9: 317-31.
143. Mahadeva R, Lomas DA. Genetics and respiratory diseas. 2. Alpha 1-antitrypsin deficiency, cirrhosis and emphysema. Thorax 1998; 53: 501-5.
144. Parmar JS, Mahadeva R, Reed BJ et al. Polymers of alpha 1-antitrypsin are chemotactic for human neutrophils: a new paradigm for the pathogenesis of emphysema. Am J Respir Cell Mol Biol 2002; 26: 723-30.
145. Elliott PR, Bilton D, Lomas DA. Lung polymers in Z alpha 1-antitrypsin deficiency-related emphysema. Am J Respir Cell Mol Biol 1998; 18: 670-4.
146. Beatty K, Bieth J, Travis J. Kinetics of association of serine proteinases with native and oxidized alpha-1-proteinase inhibitor and alpha 1-antichymotrypsin. J Biol Chem 1980; 255: 3931-4.
147. Carrell RW. alpha 1-Antitrypsin: molecular pathology, leukocytes, and tissue damage. J Clin Invest 1986; 78: 1427-31.
148. Lewis JH, Iammarino RM, Spero JA, Hasiba U. Antithrombin Pittsburgh: an alpha1-antitrypsin variant causing hemorrhagic disease. Blood 1978; 51: 129-37.
149. Owen MC, Brennan SO, Lewis JH, Carrell RW. Mutation of antitrypsin to antithrombi. Alpha 1-antitrypsin Pittsburgh (358 Met leads to Arg), a fatal bleeding disorder. New Engl J Med 1983; 309: 694-8.
150. Scott CF, Carrell RW, Glaser CB et al. Alpha 1-antitrypsin-Pittsburgh. A potent inhibitor of human plasma factor XIa, kallikrein, and factor XIIf. J Clin Invest 1986; 77: 631-4.
151. McElvaney NG, Stoller JK, Buist AS et al. Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficienc. Alpha 1-Antitrypsin Deficiency Registry Study Group. Chest 1997; 111: 394-403.
152. Silverman EK, Pierce JA, Province MA et al. Variability of pulmonary function in alpha-1-antitrypsin deficiency: clinical correlates. Ann Intern Med 1989; 111: 982-91.
153. Larsson C. Natural history and life expectancy in severe alpha1-antitrypsin deficiency, Pi Z. Acta Med Scand 1978; 204: 345-51.
154. Janus ED, Phillips NT, Carrell RW. Smoking, lung function, and alpha 1-antitrypsin deficiency. Lancet 1985; 1: 152-4.
155. Tobin MJ, Cook PJ, Hutchison DC. Alpha 1-antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi type Z. A survey by the British Thoracic Association. Br J Dis Chest 1983; 77: 14-27.
156. Black LF, Kueppers F. Alpha1-Antitrypsin deficiency in nonsmokers. Am Rev Respir Dis 1978; 117: 421-8.
157. Piitulainen E, Tornling G, Eriksson S. Effect of age and occupational exposure to airway irritants on lung function in non-smoking individuals with alpha 1-antitrypsin deficiency (Pi Z). Thorax 1997; 52: 244-8.
158. Silverman EK, Province MA, Rao DC et al. A family study of the variability of pulmonary function in alpha 1-antitrypsin deficiency. Quantitative phenotypes. Am Rev Respir Dis 1990; 142: 1015-21.
159. Silverman EK, Province MA, Campbell EJ et al. Variability of pulmonary function in alpha-1-antitrypsin deficiency: residual family resemblance beyond the effect of the Pi locus. Hum Hered 1990; 40: 340-55.
160. Novoradovsky A, Brantly ML, Waclawiw MA et al. Endothelial nitric oxide synthase as a potential susceptibility gene in the pathogenesis of emphysema in alpha1-antitrypsin deficiency. Am J Respir Cell Mol Biol 1999; 20: 441-7.
161. de Serres FJ. Worldwide racial and ethnic distribution of alpha1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys. Chest 2002; 122: 1818-29.
162. Barnett TB, Gottovi D, Johnson AM. Protease inhibitors in chronic obstructive pulmonary disease. Am Rev Respir Dis 1975; 111: 587-93.
163. Bartmann K, Fooke-Achterrath M, Koch G et al. Heterozygosity in the Pi-system as a pathogenetic cofactor in chronic obstructive pulmonary disease (COPD). Eur J Respir Dis 1985; 66: 284-96.
164. Cox DW, Hoeppner VH, Levison H. Protease inhibitors in patients with chronic obstructive pulmonary disease: the alpha 1-antitrypsin heterozygote controversy. Am Rev Respir Dis 1976; 113: 601-6.
165. Kueppers F, Donhardt A. Obstructive lung disease in heterozygotes for alpha-1 antitrypsin deficiency. Ann Intern Med 1974; 80: 209-12.
166. Kueppers F, Miller RD, Gordon H et al. Familial prevalence of chronic obstructive pulmonary disease in a matched pair study. Am J Med 1977; 63: 336-42.
167. Lieberman J, Winter B, Sastre A. Alpha 1-antitrypsin Pi-types in 965 COPD patients. Chest 1986; 89: 370-3.
168. Poller W, Meisen C, Olek K. DNA polymorphisms of the alpha 1-antitrypsin gene region in patients with chronic obstructive pulmonary disease. Eur J Clin Invest 1990; 20: 1-7.
169. Sandford AJ, Weir TD, Spinelli JJ, Pare PD. Z and S mutations of the alpha1-antitrypsin gene and the risk of chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 1999; 20: 287-91.
170. Gulsvik A, Fagerhol MK. Alpha 1-antitrypsin phenotypes and obstructive lung disease in the city of Oslo. Scand J Respir Dis 1979; 60: 267-74.
171. Klayton R, Fallat R, Cohen AB. Determinants of chronic obstructive pulmonary disease in patients with intermediate levels of alpha-antitrypsin. Am Rev Respir Dis 1975; 112: 71-5.
172. Webb DR, Hyde RW, Schwartz RH et al. Serum alpha 1-antitrypsin variants. Prevalence and clinical spirometry. Am Rev Respir Dis 1973; 108: 918-25.
173. Morse JO, Lebowitz MD, Knudson RJ, Burrows B. Relation of protease inhibitor phenotypes to obstructive lung diseases in a community. New Engl J Med 1977; 296: 1190-4.
174. Dahl M, Tybjaerg-Hansen A, Lange P et al. Change in lung function and morbidity from chronic obstructive pulmonary disease in alpha1-antitrypsin MZ heterozygotes: a longitudinal study of the general population. Ann Intern Med 2002; 136: 270-9.
175. Anthonisen NR, Connett JE, Kiley JP et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. J Am Med Assoc 1994; 272: 1497-505.
176. Hersh CP, Dahl M, Ly NP et al. Chronic obstructive pulmonary disease in alpha 1-antitrypsin PI MZ heterozygotes: a metaanalysis. Thorax 2004; 59: 843-9.
177. Larsson C, Dirksen H, Sundstrom G, Eriksson S. Lung function studies in asymptomatic individuals with moderately (Pi SZ) and severely (Pi Z) reduced levels of alpha1-antitrypsin. Scand J Respir Dis 1976; 57: 267-80.
178. Gishen P, Saunders AJ, Tobin MJ, Hutchison DC. Alpha 1- antitrypsin deficiency: the radiological features of pulmonary emphysema in subjects of Pi type Z and Pi type SZ: a survey by the British Thoracic Association. Clin Radiol 1982; 33: 371-7.
179. Hutchison DC, Tobin MJ, Cook PJ. Alpha 1 antitrypsin deficiency: clinical and physiological features in heterozygotes of Pi type SZ. A survey by the British Thoracic Association. Br J Dis Chest 1983; 77: 28-34.
180. Turino GM, Barker AF, Brantly ML et al. Clinical features of individuals with PI*SZ phenotype of alpha 1-antitrypsin deficienc. alpha 1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1996; 154: 1718-25.
181. Seersholm N, Kok-Jensen A. Intermediate alpha 1-antitrypsin deficiency PiSZ: a risk factor for pulmonary emphysema? Respir Med 1998; 92: 241-5.
182. Hall WJ, Hyde RW, Schwartz RH et al. Pulmonary abnormalities in intermediate alpha-1-antitrypsin deficiency. J Clin Invest 1976; 58: 1069-77.
183. Matzen RN, Bader PI, Block WD. alpha1-Antitrypsin deficiency in clinic patients. Ann Clin Res 1977; 9: 88-92.
184. Kalsheker NA, Hodgson IJ, Watkins GL et al. Deoxyribonucleic acid (DNA) polymorphism of the alpha 1-antitrypsin gene in chronic lung disease. Br Med J (Clin Res Ed) 1987; 294: 1511-4.
185. Kalsheker NA, Watkins GL, Hill S et al. Independent mutations in the flanking sequence of the alpha-1- antitrypsin gene are associated with chronic obstructive airways disease. Dis Markers 1990; 8: 151-7.
186. Sandford AJ, Spinelli JJ, Weir TD, Pare PD. Mutation in the 3_ region of the alpha-1-antitrypsin gene and chronic obstructive pulmonary disease. J Med Genet 1997; 34: 874-5.
187. Benetazzo MG, Gile LS, Bombieri C et al. Alpha 1-antitrypsin TAQ I polymorphism and alpha 1-antichymotrypsin mutations in patients with obstructive pulmonary disease. Respir Med 1999; 93: 648-54.
188. Morgan K, Scobie G, Kalsheker N. The characterization of a mutation of the 3_ flanking sequence of the alpha 1-antitrypsin gene commonly associated with chronic obstructive airways disease. Eur J Clin Invest 1992; 22: 134-7.
189. Morgan K, Scobie G, Marsters P, Kalsheker NA. Mutation in an alpha1-antitrypsin enhancer results in an interleukin-6 deficient acute-phase response due to loss of cooperativity between transcription factors. Biochim Biophys Acta 1997; 1362: 67-76.
190. Sandford AJ, Chagani T, Spinelli JJ, Pare PD. Alpha1- antitrypsin genotypes and the acute-phase response to open heart surgery. Am J Respir Crit Care Med 1999; 159: 1624-8.
191. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1998; 158: 49-59.
192. Seersholm N, Wencker M, Banik N et al. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J 1997; 10: 2260-3.
193. Stoller JK, Aboussouan LS. alpha1-Antitrypsin deficiency. 5: intravenous augmentation therapy: current understanding. Thorax 2004; 59: 708-12.
194. Gardi C, Cavarra E, Calzoni P et al. Neutrophil lysosomal dysfunctions in mutant C57 Bl/6J mice: interstrain variations in content of lysosomal elastase, cathepsin G and their inhibitors. Biochem J 1994; 299 (Pt 1): 237-45.
195. Wenstrup R, Zhao H. Heritable disorders of connective tissue with skin changes. In: Freedberg IM, Eisen AZ, Wolff K et al. (eds) Fitzpatrick’s dermatology in general medicine. New York: McGraw-Hill, 2003.
196. Online Mendelian Inheritance in Man, OMIM(TM). McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University, Baltimore, MD and National Center for Biotechnology Information, National Library of Medicine, Bethesda, MD, 2000.
197. Harris RB, Heaphy MR, Perry HO. Generalized elastolysis (cutis laxa). Am J Med 1978; 65: 815-22.
198. Merten DF, Rooney R. Progressive pulmonary emphysema associated with congenital generalized elastolysis (cutis laxa). Radiology 1974; 113: 691-2.
199. Mehregan AH, Lee SC, Nabai H. Cutis laxa (generalized elastolysis). A report of four cases with autopsy findings. J Cutan Pathol 1978; 5: 116-26.
200. Ledoux-Corbusier M. Cutis laxa, congenital form with pulmonary emphysema: an ultrastructural study. J Cutan Pathol 1983; 10: 340-9.
201. Turner-Stokes L, Turton C, Pope FM, Green M. Emphysema and cutis laxa. Thorax 1983; 38: 790-2.
202. Van Maldergem L, Vamos E, Liebaers I et al. Severe congenital cutis laxa with pulmonary emphysema: a family with three affected sibs. Am J Med Genet 1988; 31: 455-64.
203. Yanagisawa H, Davis EC, Starcher BC et al. Fibulin-5 is an elastin-binding protein essential for elastic fibre development in vivo. Nature 2002; 415: 168-71.
204. Nakamura T, Lozano PR, Ikeda Y et al. Fibulin-5/DANCE is essential for elastogenesis in vivo. Nature 2002; 415: 171-5.
205. Loeys B, Van Maldergem L, Mortier G et al. Homozygosity for a missense mutation in fibulin-5 (FBLN5) results in a severe form of cutis laxa. Hum Mol Genet 2002; 11: 2113-8.
206. Corbett E, Glaisyer H, Chan C et al. Congenital cutis laxa with a dominant inheritance and early onset emphysema. Thorax 1994; 49: 836-7.
207. Tassabehji M, Metcalfe K, Hurst J et al. An elastin gene mutation producing abnormal tropoelastin and abnormal elastic fibres in a patient with autosomal dominant cutis laxa. Hum Mol Genet 1998; 7: 1021-8.
208. Zhang MC, He L, Giro M et al. Cutis laxa arising from frameshift mutations in exon 30 of the elastin gene (ELN). J Biol Chem 1999; 274: 981-6.
209. Markova D, Zou Y, Ringpfeil F et al. Genetic heterogeneity of cutis laxa: a heterozygous tandem duplication within the fibulin-5 (FBLN5) gene. Am J Hum Genet 2003; 72: 998-1004.
210. Daish P, Wheeler EM, Roberts PF, Jones RD. Menkes’s syndrome. Report of a patient treated from 21 days of age with parenteral copper. Arch Dis Child 1978; 53: 956-8.
211. Peltonen L, Kuivaniemi H, Palotie A et al. Alterations in copper and collagen metabolism in the Menkes syndrome and a new subtype of the Ehlers-Danlos syndrome. Biochemistry 1983; 22: 6156-63.
212. Beighton P, De Paepe A, Steinmann B et al. Ehlers-Danlos syndromes: revised nosology, Villefranche, 1997. Ehlers-Danlos National Foundation (USA) and Ehlers-Danlos Support Group (UK). Am J Med Genet 1998; 77: 31-7.
213. Pepin M, Schwarze U, Superti-Furga A, Byers PH. Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. New Engl J Med 2000; 342: 673-80.
214. Dowton SB, Pincott S, Demmer L. Respiratory complications of Ehlers-Danlos syndrome type IV. Clin Genet 1996; 50: 510-4.
215. Dietz HC, Pyeritz RE. Marfan syndrome and related disorders. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, 2001: 5287-311.
216. Wood JR, Bellamy D, Child AH, Citron KM. Pulmonary disease in patients with Marfan syndrome. Thorax 1984; 39: 780-4.
217. Day DL, Burke BA. Pulmonary emphysema in a neonate with Marfan syndrome. Pediatr Radiol 1986; 16: 518-21.
218. Dominguez R, Weisgrau RA, Santamaria M. Pulmonary hyperinflation and emphysema in infants with the Marfan syndrome. Pediatr Radiol 1987; 17: 365-9.
219. Turner JA, Stanley NN. Fragile lung in the Marfan syndrome. Thorax 1976; 31: 771-5.
220. Dietz HC, Pyeritz RE. Mutations in the human gene for fibrillin-1 (FBN1) in the Marfan syndrome and related disorders. Hum Mol Genet 1995; 4 (Spec No): 1799-809.
221. Pereira L, Andrikopoulos K, Tian J et al. Targetting of the gene encoding fibrillin-1 recapitulates the vascular aspect of Marfan syndrome. Nat Genet 1997; 17: 218-22.
222. Neptune ER, Frischmeyer PA, Arking DE et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 2003; 33: 407-11.
223. Lubec B, Fang-Kircher S, Lubec T et al. Evidence for McKusick’s hypothesis of deficient collagen cross-linking in patients with homocystinuria. Biochim Biophys Acta 1996; 1315: 159-62.
224. Cochran FB, Sweetman L, Schmidt K et al. Pyridoxineunresponsive homocystinuria with an unusual clinical course. Am J Med Genet 1990; 35: 519-22.
225. Bass HN, LaGrave D, Mardach R et al. Spontaneous pneumothorax in association with pyridoxine-responsive homocystinuria. J Inherit Metab Dis 1997; 20: 831-2.
226. Toro JR, Glenn G, Duray P et al. Birt-Hogg-Dube syndrome: a novel marker of kidney neoplasia. Arch Dermatol 1999; 135: 1195-202.
227. Khoo SK, Giraud S, Kahnoski K et al. Clinical and genetic studies of Birt-Hogg-Dube syndrome. J Med Genet 2002; 39: 906-12.
228. Zbar B, Alvord WG, Glenn G et al. Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dube syndrome. Cancer Epidemiol Biomark Prev 2002; 11: 393-400.
229. Nickerson ML, Warren MB, Toro JR et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell 2002; 2: 157-64.
230. Verheijen FW, Verbeek E, Aula N et al. A new gene, encoding an anion transporter, is mutated in sialic acid storage diseases. Nat Genet 1999; 23: 462-5.
231. Paakko P, Ryhanen L, Rantala H, Autio-Harmainen H. Pulmonary emphysema in a nonsmoking patient with Salla disease. Am Rev Respir Dis 1987; 135: 979-82.
232. Keppler OT, Hinderlich S, Langner J et al. UDP-GlcNAc 2- epimerase: a regulator of cell surface sialylation. Science 1999; 284: 1372-6.
233. Enns GM, Seppala R, Musci TJ et al. Clinical course and biochemistry of sialuria. J Inherit Metab Dis 2001; 24: 328-36.
234. Naureckiene S, Sleat DE, Lackland H et al. Identification of HE1 as the second gene of Niemann-Pick C disease. Science 2000; 290: 2298-301.
235. Elleder M, Houstkova H, Zeman J et al. Pulmonary storage with emphysema as a sign of Niemann-Pick type C2 disease (second complementation group). Report of a case. Virchows Arch 2001; 439: 206-11.
236. Yamaki S, Horiuchi T, Takahashi T. Pulmonary changes in congenital heart disease with Down’s syndrome: their significance as a cause of postoperative respiratory failure. Thorax 1985; 40: 380-6.
237. Joshi VV, Kasznica J, Ali Khan MA et al. Cystic lung disease in Down’s syndrome: a report of two cases. Pediatr Pathol 1986; 5: 79-86.
238. Gonzalez OR, Gomez IG, Recalde AL, Landing BH. Postnatal development of the cystic lung lesion of Down syndrome: suggestion that the cause is reduced formation of peripheral air spaces. Pediatr Pathol 1991; 11: 623-33.
239. Gyves-Ray K, Kirchner S, Stein S et al. Cystic lung disease in Down syndrome. Pediatr Radiol 1994; 24: 137-8.
240. Tyrrell VJ, Asher MI, Chan Y. Subpleural lung cysts in Down’s syndrome. Pediatr Pulmonol 1999; 28: 145-8.
241. Cooney TP, Thurlbeck WM. Pulmonary hypoplasia in Down’s syndrome. New Engl J Med 1982; 307: 1170-3.
242. Sahn SA, Heffner JE. Spontaneous pneumothorax. New Engl J Med 2000; 342: 868-74.
243. Nickoladze GD. Surgical management of familial spontaneous pneumothorax. Respir Med 1990; 84: 107-9.
244. Abolnik IZ, Lossos IS, Zlotogora J, Brauer R. On the inheritance of primary spontaneous pneumothorax. Am J Med Genet 1991; 40: 155-8.
245. Morrison PJ, Lowry RC, Nevin NC. Familial primary spontaneous pneumothorax consistent with true autosomal dominant inheritance. Thorax 1998; 53: 151-2.
246. Koivisto PA, Mustonen A. Primary spontaneous pneumothorax in two siblings suggests autosomal recessive inheritance. Chest 2001; 119: 1610-2.
247. Sharpe IK, Ahmad M, Braun W. Familial spontaneous pneumothorax and HLA antigens. Chest 1980; 78: 264-8.
248. Yamada A, Takeda Y, Hayashi S, Shimizu K. Familial spontaneous pneumothorax in three generations and its HLA. Jpn J Thorac Cardiovasc Surg 2003; 51: 456-8.
249. Sugiyama Y, Maeda H, Yotsumoto H, Takaku F. Familial spontaneous pneumothorax. Thorax 1986; 41: 969-70.
250. Lenler-Petersen P, Grunnet N, Jespersen TW, Jaeger P. Familial spontaneous pneumothorax. Eur Respir J 1990; 3: 342-5.
251. Cheng YJ, Chou SH, Kao EL. Familial spontaneous pneumothorax - report of seven cases in two families. Gaoxiong Yi Xue Ke Xue Za Zhi 1992; 8: 390-4.
252. Cardy CM, Maskell NA, Handford PA et al. Familial spontaneous pneumothorax and FBN1 mutations. Am J Respir Crit Care Med 2004; 169: 1260-2.
253. Graham RB, Nolasco M, Peterlin B, Garcia CK. Nonsense mutations in folliculin presenting as isolated familial spontaneous pneumothorax in adults. Am J Resp Crit Care Med 2005 (in press).
254. Clements BS. Congenital malformations of the lungs and airways. In: Taussig LM, Laundau LI (eds) Pediatric respiratory medicine. St. Louis: Mosby, 1999: 1106-36.
255. Warner JO, Rubin S, Heard BE. Congenital lobar emphysema: a case with bronchial atresia and abnormal bronchial cartilages. Br J Dis Chest 1982; 76: 177-84.
256. Sloan H. Lobar obstructive emphysema in infancy treated by lobectomy. J Thorac Surg 1953; 26: 1-20.
257. Hendren WH, McKee DM. Lobar emphysema of infancy. J Pediat Surg 1966; 1: 24-39.
258. Wall MA, Eisenberg JD, Campbell JR. Congenital lobar emphysema in a mother and daughter. Pediatrics 1982; 70: 131-3.
259. Wisnieski JJ, Baer AN, Christensen J et al. Hypocomplementemic urticarial vasculitis syndrome. Clinical and serologic findings in 18 patients. Medicine (Balt) 1995; 74: 24-41.
260. Schwartz HR, McDuffie FC, Black LF et al. Hypocomplementemic urticarial vasculitis: association with chronic obstructive pulmonary disease. Mayo Clin Proc 1982; 57: 231-8.
261. Ghamra Z, Stoller JK. Basilar hyperlucency in a patient with emphysema due to hypocomplementemic urticarial vasculitis syndrome. Respir Care 2003; 48: 697-9.
262. Wisnieski JJ, Emancipator SN, Korman NJ et al. Hypocomplementemic urticarial vasculitis syndrome in identical twins. Arthritis Rheum 1994; 37: 1105-11.
263. Knudson RJ. James Jackson Jr, the young pulmonologist who described familial emphysema. An historical footnote. Chest 1985; 87: 673-6.
264. Hurst A. Familial emphysema. Am Rev Respir Dis 1959; 80: 179-80.
265. Wimpfheimer F, Schneider L. Familial emphysema. Am Rev Respir Dis 1961; 83: 697-703.
266. Larson RK, Barman ML. The familial occurrence of chronic obstructive pulmonary disease. Ann Intern Med 1965; 63: 1001-8.
267. Hole BV, Wasserman K. Familial emphysema. Ann Intern Med 1965; 63: 1009-17.
268. Cederlof R, Friberg L, Jonsson E, Kaij L. Morbidity among monozygotic twins. Arch Environ Health 1965; 10: 346-50.
269. Cederlof R, Edfors ML, Friberg L, Jonsson E. Hereditary factors, ‘spontaneous cough’ and ‘smoker’s cough’. A study on 7800 twin-pairs with the aid of mailed questionnaires. Arch Environ Health 1967; 14: 401-6.
270. Nelson P, Kanner RE. Bullous emphysema in monozygotic twins. Am Rev Respir Dis 1989; 140: 1796-9.
271. Speizer FE, Rosner B, Tager I. Familial aggregation of chronic respiratory disease: use of National Health Interview Survey data for specific hypothesis testing. Int J Epidemiol 1976; 5: 167-72.
272. Tager I, Tishler PV, Rosner B et al. Studies of the familial aggregation of chronic bronchitis and obstructive airways disease. Int J Epidemiol 1978; 7: 55-62.
273. Larson RK, Barman ML, Kueppers F, Fudenberg HH. Genetic and environmental determinants of chronic obstructive pulmonary disease. Ann Intern Med 1970; 72: 627-32.
274. Cohen BH, Ball WC Jr, Bias WB et al. A genetic-epidemiologic study of chronic obstructive pulmonary disease. I. Study design and preliminary observations. Johns Hopkins Med J 1975; 137: 95-104.
275. Cohen BH, Ball WC Jr, Brashears S et al. Risk factors in chronic obstructive pulmonary disease (COPD). Am J Epidemiol 1977; 105: 223-32.
276. Cohen BH. Chronic obstructive pulmonary disease: a challenge in genetic epidemiology. Am J Epidemiol 1980; 112: 274-88.
277. Khoury MJ, Beaty TH, Tockman MS et al. Familial aggregation in chronic obstructive pulmonary disease: use of the loglinear model to analyze intermediate environmental and genetic risk factors. Genet Epidemiol 1985; 2: 155-66.
278. Khoury MJ, Beaty TH, Newill CA et al. Genetic-environmental interactions in chronic airways obstruction. Int J Epidemiol 1986; 15: 65-72.
279. Montnemery P, Lanke J, Lindholm LH et al. Familial related risk-factors in the development of chronic bronchitis/emphysema as compared to asthma assessed in a postal survey. Eur J Epidemiol 2000; 16: 1003-7.
280. Silverman EK, Chapman HA, Drazen JM et al. Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis. Am J Respir Crit Care Med 1998; 157: 1770-8.
281. Celedón JC, Speizer FE, Drazen JM et al. Bronchodilator responsiveness and serum total IgE levels in families of probands with severe early-onset COPD. Eur Respir J 1999; 14: 1009-14.
282. Silverman EK, Weiss ST, Drazen JM et al. Gender-related differences in severe, early-onset chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162: 2152-8.
283. DeMeo DL, Carey VJ, Chapman HA et al. Familial aggregation of FEF(25-75) and FEF(25-75)/FVC in families with severe, early onset COPD. Thorax 2004; 59: 396-400.
284. McCloskey SC, Patel BD, Hinchliffe SJ et al. Siblings of patients with severe chronic obstructive pulmonary disease have a significant risk of airflow obstruction. Am J Respir Crit Care Med 2001; 164: 1419-24.
285. Silverman EK, Palmer LJ, Mosley JD et al. Genomewide linkage analysis of quantitative spirometric phenotypes in severe early-onset chronic obstructive pulmonary disease. Am J Hum Genet 2002; 70: 1229-39.
286. Silverman EK, Mosley JD, Palmer LJ et al. Genome-wide linkage analysis of severe, early-onset chronic obstructive pulmonary disease: airflow obstruction and chronic bronchitis phenotypes. Hum Mol Genet 2002; 11: 623-32.
287. Lander E, Kruglyak L. Genetic dissection of complex traits: Guidelines for interpreting and reporting linkage results. Nat Genet 1995; 11: 241-7.
288. Palmer LJ, Celedon JC, Chapman HA et al. Genome-wide linkage analysis of bronchodilator responsiveness and postbronchodilator spirometric phenotypes in chronic obstructive pulmonary disease. Hum Mol Genet 2003; 12: 1199-210.
289. Hakonarson H, Halapi E, Sigvaldason A et al. A linkage study in heavy smokers identifies both causative and protective genes for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169: A506.
290. DeMeo DL, Celedon JC, Lange C et al. Genomewide linkage of forced mid-expiratory flow in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 1294-301.
291. Celedon JC, Lange C, Raby BA et al. The transforming growth factor-1 (TGFB1) gene is associated with chronic obstructive pulmonary disease (COPD). Hum Mol Genet 2004; 13: 1649-1656.
292. Billingsley GD, Walter MA, Hammond GL, Cox DW. Physical mapping of four serpin genes: alpha 1-antitrypsin, alpha 1-antichymotrypsin, corticosteroid-binding globulin, and protein C inhibitor, within a 280-kb region on chromosome I4q32.1. Am J Hum Genet 1993; 52: 343-53.
293. Eriksson S, Lindmark B, Lilja H. Familial alpha 1-antichymotrypsin deficiency. Acta Med Scand 1986; 220: 447-53.
294. Lindmark BE, Arborelius M Jr, Eriksson SG. Pulmonary function in middle-aged women with heterozygous deficiency of the serine protease inhibitor alpha 1-antichymotrypsin. Am Rev Respir Dis 1990; 141: 884-8.
295. Poller W, Faber JP, Scholz S et al. Mis-sense mutation of alpha 1-antichymotrypsin gene associated with chronic lung disease. Lancet 1992; 339: 1538.
296. Samilchuk EI, Chuchalin AG. Mis-sense mutation of alpha 1-antichymotrypsin gene and chronic lung disease. Lancet 1993; 342: 624.
297. Poller W, Faber JP, Weidinger S et al. A leucine-to-proline substitution causes a defective alpha 1-antichymotrypsin allele associated with familial obstructive lung disease. Genomics 1993; 17: 740-3.
298. Sandford AJ, Chagani T, Weir TD, Pare PD. Alpha 1-antichymotrypsin mutations in patients with chronic obstructive pulmonary disease. Dis Markers 1998; 13: 257-60.
299. Ishii T, Matsuse T, Teramoto S et al. Association between alpha-1-antichymotrypsin polymorphism and susceptibility to chronic obstructive pulmonary disease. Eur J Clin Invest 2000; 30: 543-8.
300. White R, Janoff A, Godfrey HP. Secretion of alpha-2- macroglobulin by human alveolar macrophages. Lung 1980; 158: 9-14.
301. Bergqvist D, Nilsson IM. Hereditary alpha 2-macroglobulin deficiency. Scand J Haematol 1979; 23: 433-6.
302. Poller W, Barth J, Voss B. Detection of an alteration of the alpha 2-macroglobulin gene in a patient with chronic lung disease and serum alpha 2-macroglobulin deficiency. Hum Genet 1989; 83: 93-6.
303. Poller W, Faber JP, Klobeck G, Olek K. Cloning of the human alpha 2-macroglobulin gene and detection of mutations in two functional domains: the bait region and the thiolester site. Hum Genet 1992; 88: 313-9.
304. Shapiro SD. Elastolytic metalloproteinases produced by human mononuclear phagocytes. Potential roles in destructive lung disease. Am J Respir Crit Care Med 1994; 150: S160-4.
305. Parks WC, Shapiro SD. Matrix metalloproteinases in lung biology. Respir Res 2001; 2: 10-9.
306. Hautamaki RD, Kobayashi DK, Senior RM, Shapiro SD. Requirement for macrophage elastase for cigarette smokeinduced emphysema in mice. Science 1997; 277: 2002-4.
307. D’Armiento J, Dalal SS, Okada Y et al. Collagenase expression in the lungs of transgenic mice causes pulmonary emphysema. Cell 1992; 71: 955-61.
308. Finlay GA, O’Driscoll LR, Russell KJ et al. Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. Am J Respir Crit Care Med 1997; 156: 240-7.
309. Zhang B, Ye S, Herrmann SM et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999; 99: 1788-94.
310. Minematsu N, Nakamura H, Tateno H et al. Genetic polymorphism in matrix metalloproteinase-9 and pulmonary emphysema. Biochem Biophys Res Commun 2001; 289: 116-9.
311. Joos L, He JQ, Shepherdson MB et al. The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function. Hum Mol Genet 2002; 11: 569-76.
312. Hirano K, Sakamoto T, Uchida Y et al. Tissue inhibitor of metalloproteinases-2 gene polymorphisms in chronic obstructive pulmonary disease. Eur Respir J 2001; 18: 748-52.
313. Barnes PJ. New concepts in chronic obstructive pulmonary disease. Annu Rev Med 2003; 54: 113-29.
314. Rahman I, MacNee W. Role of oxidants/antioxidants in smoking-induced lung diseases. Free Radic Biol Med 1996; 21: 669-81.
315. MacNee W. Oxidants/antioxidants and COPD. Chest 2000; 117: 303S-17S.
316. Morse D, Choi AM. Heme oxygenase-1: the ‘emerging molecule’ has arrived. Am J Respir Cell Mol Biol 2002; 27: 8-16.
317. Maestrelli P, El Messlemani AH, De Fina O et al. Increased expression of heme oxygenase (HO)-1 in alveolar spaces and HO-2 in alveolar walls of smokers. Am J Respir Crit Care Med 2001; 164: 1508-13.
318. He JQ, Ruan J, Connett JE et al. Antioxidant gene polymorphisms and susceptibility to a rapid decline in lung function in smokers. Am J Respir Crit Care Med 2002; 166: 323-8.
319. Hassett C, Aicher L, Sidhu JS, Omiecinski CJ. Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Hum Mol Genet 1994; 3: 421-8.
320. Paolini M, Chieco P. Polymorphism in gene for microsomal epoxide hydrolase and lung disease. Lancet 1997; 350: 1554.
321. Smith CA, Harrison DJ. Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet 1997; 350: 630-3.
322. Yoshikawa M, Hiyama K, Ishioka S et al. Microsomal epoxide hydrolase genotypes and chronic obstructive pulmonary disease in Japanese. Int J Mol Med 2000; 5: 49-53.
323. Takeyabu K, Yamaguchi E, Suzuki I et al. Gene polymorphism for microsomal epoxide hydrolase and susceptibility to emphysema in a Japanese population. Eur Respir J 2000; 15: 891-4.
324. Budhi A, Hiyama K, Isobe T et al. Genetic susceptibility for emphysematous changes of the lung in Japanese. Int J Mol Med 2003; 11: 321-9.
325. Yim JJ, Park GY, Lee CT et al. Genetic susceptibility to chronic obstructive pulmonary disease in Koreans: combined analysis of polymorphic genotypes for microsomal epoxide hydrolase and glutathione S-transferase M1 and T1. Thorax 2000; 55: 121-5.
326. Cheng SL, Yu CJ, Chen CJ, Yang PC. Genetic polymorphism of epoxide hydrolase and glutathione S-transferase in COPD. Eur Respir J 2004; 23: 818-24.
327. Xiao D, Wang C, Du MJ et al. Relationship between polymorphisms of genes encoding microsomal epoxide hydrolase and glutathione S-transferase P1 and chronic obstructive pulmonary disease. Chin Med J (Engl) 2004; 117: 661-7.
328. Zhang R, Zhang A, He Q, Lu B. [Microsomal epoxide hydrolase gene polymorphism and susceptibility to chronic obstructive pulmonary disease in Han nationality of North China]. Zhonghua Nei Ke Za Zhi 2002; 41: 11-4.
329. Board P, Coggan M, Johnston P et al. Genetic heterogeneity of the human glutathione transferases: a complex of gene families. Pharmacol Ther 1990; 48: 357-69.
330. Hengstler JG, Arand M, Herrero ME, Oesch F. Polymorphisms of N-acetyltransferases, glutathione S-transferases, microsomal epoxide hydrolase and sulfotransferases: influence on cancer susceptibility. Rec Res Cancer Res 1998; 154: 47-85.
331. Engel LS, Taioli E, Pfeiffer R et al. Pooled analysis and metaanalysis of glutathione S-transferase M1 and bladder cancer: a HuGE review. Am J Epidemiol 2002; 156: 95-109.
332. Harrison DJ, Cantlay AM, Rae F et al. Frequency of glutathione S-transferase M1 deletion in smokers with emphysema and lung cancer. Hum Exp Toxicol 1997; 16: 356-60.
333. Baranova H, Perriot J, Albuisson E et al. Peculiarities of the GSTM1 0/0 genotype in French heavy smokers with various types of chronic bronchitis. Hum Genet 1997; 99: 822-6.
334. Cantlay AM, Smith CA, Wallace WA et al. Heterogeneous expression and polymorphic genotype of glutathione S-transferases in human lung. Thorax 1994; 49: 1010-4.
335. Sundberg K, Johansson AS, Stenberg G et al. Differences in the catalytic efficiencies of allelic variants of glutathione transferase P1-1 towards carcinogenic diol epoxides of polycyclic aromatic hydrocarbons. Carcinogenesis 1998; 19: 433-6.
336. Ishii T, Matsuse T, Teramoto S et al. Glutathione S-transferase P1 (GSTP1) polymorphism in patients with chronic obstructive pulmonary disease. Thorax 1999; 54: 693-6.
337. Yim JJ, Yoo CG, Lee CT et al. Lack of association between glutathione S-transferase P1 polymorphism and COPD in Koreans. Lung 2002; 180: 119-25.
338. Lu B, He Q. [Correlation between exon5 polymorphism of glutathione S-transferase P1 gene and susceptibility to chronic obstructive pulmonary disease in northern Chinese population of Han nationality living in Beijing, China]. Zhonghua Nei Ke Za Zhi 2002; 41: 678-81.
339. Cantlay AM, Lamb D, Gillooly M et al. Association between the CYP1A1 gene polymorphism and susceptibility to emphysema and lung cancer. J Clin Pathol: Mol Pathol 1995; 48: 210M-4M.
340. Minematsu N, Nakamura H, Iwata M et al. Association of CYP2A6 deletion polymorphism with smoking habit and development of pulmonary emphysema. Thorax 2003; 58: 623-8.
341. Ishii T, Keicho N, Teramoto S et al. [Genetic variation of NADPH/NADH oxidase and susceptibility to diffuse panbronchiolitis (DPB) and chronic obstructive pulmonary disease (COPD)]. Nihon Kokyuki Gakkai Zasshi 2001; 39: 328-32.
342. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996; 153: 530-4.
343. Aaron SD, Angel JB, Lunau M et al. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 349-55.
344. Wilson AG, Symons JA, McDowell TL et al. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997; 94: 3195-9.
345. Dunham I, Sargent CA, Trowsdale J, Campbell RD. Molecular mapping of the human major histocompatibility complex by pulsed-field gel electrophoresis. Proc Natl Acad Sci USA 1987; 84: 7237-41.
346. Huang SL, Su CH, Chang SC. Tumor necrosis factor-alpha gene polymorphism in chronic bronchitis. Am J Respir Crit Care Med 1997; 156: 1436-9.
347. Sakao S, Tatsumi K, Igari H et al. Association of tumor necrosis factor alpha gene promoter polymorphism with the presence of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 420-2.
348. Sakao S, Tatsumi K, Igari H et al. Association of tumor necrosis factor-alpha gene promoter polymorphism with low attenuation areas on high-resolution CT in patients with COPD. Chest 2002; 122: 416-20.
349. Higham MA, Pride NB, Alikhan A, Morrell NW. Tumour necrosis factor-alpha gene promoter polymorphism in chronic obstructive pulmonary disease. Eur Respir J 2000; 15: 281-4.
350. Keatings VM, Cave SJ, Henry MJ et al. A polymorphism in the tumor necrosis factor-alpha gene promoter region may predispose to a poor prognosis in COPD. Chest 2000; 118: 971-5.
351. Patuzzo C, Gile LS, Zorzetto M et al. Tumor necrosis factor gene complex in COPD and disseminated bronchiectasis. Chest 2000; 117: 1353-8.
352. Ferrarotti I, Zorzetto M, Beccaria M et al. Tumour necrosis factor family genes in a phenotype of COPD associated with emphysema. Eur Respir J 2003; 21: 444-9.
353. Kucukaycan M, Van Krugten M, Pennings HJ et al. Tumor necrosis factor-alpha+ 489G/A gene polymorphism is associated with chronic obstructive pulmonary disease. Respir Res 2002; 3: 29.
354. Ishii T, Matsuse T, Teramoto S et al. Neither IL-1beta, IL-1 receptor antagonist, nor TNF-alpha polymorphisms are associated with susceptibility to COPD. Respir Med 2000; 94: 847-51.
355. Chung KF. Cytokines in chronic obstructive pulmonary disease. Eur Respir J Suppl 2001; 34: 50s-9s.
356. Joos L, McIntyre L, Ruan J et al. Association of IL-1beta and IL-1 receptor antagonist haplotypes with rate of decline in lung function in smokers. Thorax 2001; 56: 863-6.
357. McCormack FX, Whitsett JA. The pulmonary collectins, SP-A and SP-D, orchestrate innate immunity in the lung. J Clin Invest 2002; 109: 707-12.
358. Wert SE, Yoshida M, LeVine AM et al. Increased metalloproteinase activity, oxidant production, and emphysema in surfactant protein D gene-inactivated mice. Proc Natl Acad Sci USA 2000; 97: 5972-7.
359. Guo X, Lin HM, Lin Z et al. Surfactant protein gene A, B, and D marker alleles in chronic obstructive pulmonary disease of a Mexican population. Eur Respir J 2001; 18: 482-90.
360. Gabolde M, Guilloud-Bataille M, Feingold J, Besmond C. Association of variant alleles of mannose binding lectin with severity of pulmonary disease in cystic fibrosis: cohort study. Br Med J 1999; 319: 1166-7.
361. Garred P, Madsen HO, Halberg P et al. Mannose-binding lectin polymorphisms and susceptibility to infection in systemic lupus erythematosus. Arthritis Rheum 1999; 42: 2145-52.
362. Yang IA, Seeney SL, Wolter JM et al. Mannose-binding lectin gene polymorphism predicts hospital admissions for COPD infections. Genes Immun 2003; 4: 269-74.
363. Schutte BC, McCray PB Jr. Beta-defensins in lung host defense. Annu Rev Physiol 2002; 64: 709-48.
364. Matsushita I, Hasegawa K, Nakata K et al. Genetic variants of human beta-defensin-1 and chronic obstructive pulmonary disease. Biochem Biophys Res Commun 2002; 291: 17-22.
365. Ballow M. Primary immunodeficiency disorders: antibody deficiency. J Allergy Clin Immunol 2002; 109: 581-91.
366. Webb DR, Condemi JJ. Selective immunoglobulin A deficiency and chronic obstructive lung disease. A family study. Ann Intern Med 1974; 80: 618-21.
367. Bjorkander J, Bake B, Oxelius VA, Hanson LA. Impaired lung function in patients with IgA deficiency and low levels of IgG2 or IgG3. New Engl J Med 1985; 313: 720-4.
368. O’Keeffe S, Gzel A, Drury R et al. Immunoglobulin G subclasses and spirometry in patients with chronic obstructive pulmonary disease. Eur Respir J 1991; 4: 932-6.
369. Kauffmann F, Kleisbauer JP, Cambon-De-Mouzon A et al. Genetic markers in chronic air-flow limitation. A genetic epidemiologic study. Am Rev Respir Dis 1983; 127: 263-9.
370. Anagnostopoulou U, Toumbis M, Konstantopoulos K et al. HLA-A and -B antigens in chronic bronchitis. J Clin Epidemiol 1993; 46: 1413-6.
371. Horne SL, Cockcroft DW, Dosman JA. Possible protective effect against chronic obstructive airways disease by the GC2 allele. Hum Hered 1990; 40: 173-6.
372. Schellenberg D, Pare PD, Weir TD et al. Vitamin D binding protein variants and the risk of COPD. Am J Respir Crit Care Med 1998; 157: 957-61.
373. Kasuga I, Pare PD, Ruan J et al. Lack of association of group specific component haplotypes with lung function in smokers. Thorax 2003; 58: 790-3.
374. Ishii T, Keicho N, Teramoto S et al. Association of Gc-globulin variation with susceptibility to COPD and diffuse panbronchiolitis. Eur Respir J 2001; 18: 753-7.
375. Ito I, Nagai S, Hoshino Y et al. Risk and severity of COPD is associated with the group-specific component of serum globulin 1F allele. Chest 2004; 125: 63-70.
376. Laufs J, Andrason H, Sigvaldason A et al. Association of vitamin D binding protein variants with chronic mucus hypersecretion in Iceland. Am J Pharmacogenomics 2004; 4: 63-8.
377. Sluiter HJ, Koeter GH, de Monchy JG et al. The Dutch hypothesis (chronic non-specific lung disease) revisited. Eur Respir J 1991; 4: 479-89.
378. Vestbo J, Prescott E. Update on the ‘Dutch hypothesis’ for chronic respiratory disease. Thorax 1998; 53 (Suppl. 2): S15-9.
379. Boezen HM, Schouten JP, Weiss ST. The Dutch hypothesis on chronic nonspecific lung disease. In: Annesi-Maesano I, Gulsvik A, Viegi G (eds) Respiratory epidemiology in Europe. Sheffield, UK: European Respiratory Society, 2000: 37-47.
380. Raby BA, Weiss ST. Beta 2-adrenergic receptor genetics. Curr Opin Mol Ther 2001; 3: 554-66.
381. Summerhill E, Leavitt SA, Gidley H et al. Beta 2-adrenergic receptor Arg16/Arg16 genotype is associated with reduced lung function, but not with asthma, in the Hutterites. Am J Respir Crit Care Med 2000; 162: 599-602.
382. Ho LI, Harn HJ, Chen CJ, Tsai NM. Polymorphism of the beta 2-adrenoceptor in COPD in Chinese subjects. Chest 2001; 120: 1493-9.
383. Joos L, Weir TD, Connett JE et al. Polymorphisms in the beta 2 adrenergic receptor and bronchodilator response, bronchial hyperresponsiveness, and rate of decline in lung function in smokers. Thorax 2003; 58: 703-7.
384. Wills-Karp M. The gene encoding interleukin-13: a susceptibility locus for asthma and related traits. Respir Res 2000; 1: 19-23.
385. He JQ, Connett JE, Anthonisen NR, Sandford AJ. Polymorphisms in the IL13, IL13RA1, and IL4RA genes and rate of decline in lung function in smokers. Am J Respir Cell Mol Biol 2003; 28: 379-85.
386. van der Pouw Kraan TC, Kucukaycan M, Bakker AM et al. Chronic obstructive pulmonary disease is associated with the -1055 IL-13 promoter polymorphism. Genes Immun 2002; 3: 436-9.
387. Ruse CE, Hill MC, Burton PR et al. Associations between polymorphisms of the high-affinity immunoglobulin E receptor and late-onset airflow obstruction in older populations. J Am Geriatr Soc 2003; 51: 1265-9.
388. Welsh MJ, Ramsey BW, Accurso F, Cutting GR. Cystic fibrosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 8th edn. New York: McGraw-Hill, 2001: 5121-88.
389. Wood JA, Fishman AP, Reemtsma K et al. A comparison of sweat chlorides and intestinal fat absorption in chronic obstructive pulmonary emphysema and fibrocystic disease of the pancreas. New Engl J Med 1959; 260: 951-7.
390. Anderson CM, Freeman M, Allan J, Hubbard L. Observations on (i) sweat sodium levels in relation to chronic respiratory disease in adults and (ii) the incidence of respiratory and other disease in parents and siblings of patients with fibrocystic disease of the pancreas. Med J Aust 1962; 49: 965-9.
391. Batten J, Muir D, Simon G, Carter C. The prevalence of respiratory disease in heterozygotes for the gene for fibrocystic disease of the pancreas. Lancet 1963; 1: 1348-50.
392. Hallett WY, Knudson AG Jr, Massey FJ Jr. Absence of detrimental effect of the carrier state for the cystic fibrosis gene. Am Rev Respir Dis 1965; 92: 714-24.
393. Davis PB, Vargo K. Pulmonary abnormalities in obligate heterozygotes for cystic fibrosis. Thorax 1987; 42: 120-5.
394. Dumur V, Lafitte JJ, Gervais R et al. Abnormal distribution of cystic fibrosis delta F508 allele in adults with chronic bronchial hypersecretion. Lancet 1990; 335: 1340.
395. Kostuch M, Semczuk A, Szarewicz-Adamczyk W et al. Detection of CFTR gene mutations in patients suffering from chronic bronchitis. Arch Med Res 2000; 31: 97-100.
396. Artlich A, Boysen A, Bunge S et al. Common CFTR mutations are not likely to predispose to chronic bronchitis in northern Germany. Hum Genet 1995; 95: 226-8.
397. Gervais R, Lafitte JJ, Dumur V et al. Sweat chloride and delta F508 mutation in chronic bronchitis or bronchiectasis. Lancet 1993; 342: 997.
398. Dahl M, Tybjaerg-Hansen A, Lange P, Nordestgaard BG. DeltaF508 heterozygosity in cystic fibrosis and susceptibility to asthma. Lancet 1998; 351: 1911-3.
399. Dahl M, Nordestgaard BG, Lange P, Tybjaerg-Hansen A. Fifteen-year follow-up of pulmonary function in individuals heterozygous for the cystic fibrosis phenylalanine-508 deletion. J Allergy Clin Immunol 2001; 107: 818-23.
400. Tzetis M, Efthymiadou A, Strofalis S et al. CFTR gene mutations - including three novel nucleotide substitutions - and haplotype background in patients with asthma, disseminated bronchiectasis and chronic obstructive pulmonary disease. Hum Genet 2001; 108: 216-21.
401. Beaty TH, Menkes HA, Cohen BH, Newill CA. Risk factors associated with longitudinal change in pulmonary function. Am Rev Respir Dis 1984; 129: 660-7.
402. Krzyzanowski M, Jedrychowski W, Wysocki M. Factors associated with the change in ventilatory function and the development of chronic obstructive pulmonary disease in a 13-year follow-up of the Cracow Study. Risk of chronic obstructive pulmonary disease. Am Rev Respir Dis 1986; 134: 1011-9.
403. Higgins MW, Keller JB, Becker M et al. An index of risk for obstructive airways disease. Am Rev Respir Dis 1982; 125: 144-51.
404. Horne SL, Cockcroft DW, Lovegrove A, Dosman JA. ABO, Lewis and secretor status and relative incidence of air flow obstruction. Dis Markers 1985; 3: 55-62.
405. Vestbo J, Hein HO, Suadicani P et al. Genetic markers for chronic bronchitis and peak expiratory flow in the Copenhagen Male Study. Dan Med Bull 1993; 40: 378-80.
406. Spitalnik PF, Spitalnik SL. Human blood group antigens and antibodies. In: Hoffman R, Benz EJJ, Shattil SJ et al. (eds) Hematology: basic principles and practice, 3rd edn. Philadelphia: Churchill Livingstone, 2000: 2188-205.
407. Cohen BH, Bias WB, Chase GA et al. Is ABH nonsecretor status a risk factor for obstructive lung disease? Am J Epidemiol 1980; 111: 285-91.
408. Haines AP, Imeson JD, Meade TW. ABH secretor status and pulmonary function. Am J Epidemiol 1982; 115: 367-70.
409. Kauffmann F, Frette C, Pham QT et al. Associations of blood group-related antigens to FEV1, wheezing, and asthma. Am J Respir Crit Care Med 1996; 153: 76-82.
410. Abboud RT, Yu P, Chan-Yeung M, Tan F. Lack of relationship between ABH secretor status and lung function in pulp mill workers. Am Rev Respir Dis 1982; 126: 1089-91.
411. Suadicani P, Hein HO, Meyer HW, Gyntelberg F. Exposure to cold and draught, alcohol consumption, and the NS-phenotype are associated with chronic bronchitis: an epidemiological investigation of 3387 men aged 53-75 years: the Copenhagen Male Study. Occup Environ Med 2001; 58: 160-4.
412. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. New Engl J Med 2000; 342: 1350-8.
413. Bartram U, Speer CP. The role of transforming growth factor beta in lung development and disease. Chest 2004; 125: 754-65.
414. Wu L, Chau J, Young RP et al. Transforming growth factorbeta 1 genotype and susceptibility to chronic obstructive pulmonary disease. Thorax 2004; 59: 126-9.
415. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet 2001; 29: 306-9.
416. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies. Genet Med 2002; 4: 45-61.
417. Shapiro SD. Animal models for chronic obstructive pulmonary disease: age of klotho and marlboro mice. Am J Respir Cell Mol Biol 2000; 22: 4-7.
418. Mahadeva R, Shapiro SD. Chronic obstructive pulmonary disease *3: Experimental animal models of pulmonary emphysema. Thorax 2002; 57: 908-14.
419. Gross P, Pfitzer EA, Tolker E et al. Experimental emphysema: its production with papain in normal and silicotic rats. Arch Environ Health 1965; 11: 50-8.
420. Wright JL, Churg A. Cigarette smoke causes physiologic and morphologic changes of emphysema in the guinea pig. Am Rev Respir Dis 1990; 142: 1422-8.
421. Kielty CM, Raghunath M, Siracusa LD et al. The tight skin mouse: demonstration of mutant fibrillin-1 production and assembly into abnormal microfibrils. J Cell Biol 1998; 140: 1159-66.
422. Gordi C, Martorana PA, van Even P et al. Serum antielastase deficiency in tight-skin mice with genetic emphysema. Exp Mol Pathol 1990; 52: 46-53.
423. Huang L, Kuo YM, Gitschier J. The pallid gene encodes a novel, syntaxin 13-interacting protein involved in platelet storage pool deficiency. Nat Genet 1999; 23: 329-32.
424. Martorana PA, Brand T, Gardi C et al. The pallid mous. A model of genetic alpha 1-antitrypsin deficiency. Lab Invest 1993; 68: 233-41.
425. Keil M, Lungarella G, Cavarra E et al. A scanning electron microscopic investigation of genetic emphysema in tightskin, pallid, and beige mice, three different C57 BL/6J mutants. Lab Invest 1996; 74: 353-62.
426. Barbosa MD, Nguyen QA, Tchernev VT et al. Identification of the homologous beige and Chediak-Higashi syndrome genes. Nature 1996; 382: 262-5.
427. Leco KJ, Waterhouse P, Sanchez OH et al. Spontaneous air space enlargement in the lungs of mice lacking tissue inhibitor of metalloproteinases-3 (TIMP-3). J Clin Invest 2001; 108: 817-29.
428. Morris DG, Huang X, Kaminski N et al. Loss of integrin alpha(v)beta6-mediated TGF-beta activation causes Mmp12- dependent emphysema. Nature 2003; 422: 169-73.
429. Zheng T, Zhu Z, Wang Z et al. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase - and cathepsin-dependent emphysema. J Clin Invest 2000; 106: 1081-93.
430. Wang Z, Zheng T, Zhu Z et al. Interferon gamma induction of pulmonary emphysema in the adult murine lung. J Exp Med 2000; 192: 1587-600.
431. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002; 113: 59-65.
432. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980; 93: 391-8.
433. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981; 1: 681-6.
434. Calverley PM, Walker P. Chronic obstructive pulmonary disease. Lancet 2003; 362: 1053-61.
435. Palmer LJ, Silverman ES, Weiss ST, Drazen JM. Pharmacogenetics of asthma. Am J Respir Crit Care Med 2002; 165: 861-6.
436. Hosenpud JD, Bennett LE, Keck BM et al. The Registry of the International Society for Heart and Lung Transplantation: eighteenth Official Report, 2001. J Heart Lung Transplant 2001; 20: 805-15.
437. Hosenpud JD, Bennett LE, Keck BM et al. Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease. Lancet 1998; 351: 24-7.
438. Charman SC, Sharples LD, McNeil KD, Wallwork J. Assessment of survival benefit after lung transplantation by patient diagnosis. J Heart Lung Transplant 2002; 21: 226-32.
439. Ramsey SD, Berry K, Etzioni R et al. Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. New Engl J Med 2003; 348: 2092-102.
440. Spira A, Beane J, Pinto-Plata V et al. Gene expression profiling of human lung tissue from smokers with severe emphysema. Am J Respir Cell Mol Biol 2004; 31: 601-10.
441. Hackett NR, Heguy A, Harvey BG et al. Variability of antioxidant-related gene expression in the airway epithelium of cigarette smokers. Am J Respir Cell Mol Biol 2003; 29: 331-43.
442. Cigarette smoking among adults - United States, 2000. Morb Mortal Wkly Rep 2002; ss51: 642-5.
443. Arinami T, Ishiguro H, Onaivi ES. Polymorphisms in genes involved in neurotransmission in relation to smoking. Eur J Pharmacol 2000; 410: 215-26.
444. Benowitz NL. Drug therapy. Pharmacologic aspects of cigarette smoking and nicotine addition. New Engl J Med 1988; 319: 1318-30.
445. Fagerstrom KO, Schneider NG. Measuring nicotine dependence: a review of the Fagerstrom Tolerance Questionnaire. J Behav Med 1989; 12: 159-82.
446. Henningfield JE, Clayton R, Pollin W. Involvement of tobacco in alcoholism and illicit drug use. Br J Addict 1990; 85: 279-91.
447. Breslau N, Fenn N, Peterson EL. Early smoking initiation and nicotine dependence in a cohort of young adults. Drug Alcohol Depend 1993; 33: 129-37.
448. Niu T, Chen C, Ni J et al. Nicotine dependence and its familial aggregation in Chinese. Int J Epidemiol 2000; 29: 248-52.
449. Carmelli D, Swan GE, Robinette D, Fabsitz R. Genetic influence on smoking - a study of male twins. New Engl J Med 1992; 327: 829-33.
450. Heath AC, Martin NG. Genetic models for the natural history of smoking: evidence for a genetic influence on smoking persistence. Addict Behav 1993; 18: 19-34.
451. True WR, Heath AC, Scherrer JF et al. Genetic and environmental contributions to smoking. Addiction 1997; 92: 1277-87.
452. True WR, Xian H, Scherrer JF et al. Common genetic vulnerability for nicotine and alcohol dependence in men. Arch Gen Psych 1999; 56: 655-61.
453. Kendler KS, Neale MC, Sullivan P et al. A population-based twin study in women of smoking initiation and nicotine dependence. Psychol Med 1999; 29: 299-308.
454. Fisher RA. Lung cancer and cigarettes. Nature 1958; 182: 108.
455. Fisher RA. Cancer and smoking. Nature 1958; 182: 596.
456. Sullivan PF, Kendler KS. The genetic epidemiology of smoking. Nicotine Tob Res 1999; 1 (Suppl. 2): S51-7; discussion S69-70.
457. Kendler KS, Thornton LM, Pedersen NL. Tobacco consumption in Swedish twins reared apart and reared together. Arch Gen Psych 2000; 57: 886-92.
458. Li MD. The genetics of smoking related behavior: a brief review. Am J Med Sci 2003; 326: 168-73.
459. Li MD, Cheng R, Ma JZ, Swan GE. A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins. Addiction 2003; 98: 23-31.
460. Straub RE, Sullivan PF, Ma Y et al. Susceptibility genes for nicotine dependence: a genome scan and followup in an independent sample suggest that regions on chromosomes 2, 4, 10, 16, 17 and 18 merit further study. Mol Psychiatry 1999; 4: 129-44.
461. Duggirala R, Almasy L, Blangero J. Smoking behavior is under the influence of a major quantitative trait locus on human chromosome 5q. Genet Epidemiol 1999; 17 (Suppl. 1): S139-44.
462. Bergen AW, Korczak JF, Weissbecker KA, Goldstein AM. A genome-wide search for loci contributing to smoking and alcoholism. Genet Epidemiol 1999; 17 (Suppl. 1): S55-60.
463. Bierut LJ, Rice JP, Goate A et al. A genomic scan for habitual smoking in families of alcoholics: common and specific genetic factors in substance dependence. Am J Med Genet 2004; 124A: 19-27.
464. Li MD, Ma JZ, Cheng R et al. A genome-wide scan to identify loci for smoking rate in the Framingham Heart Study population. BMC Genet 2003; 4 (Suppl. 1): S103.
465. Walton R, Johnstone E, Munafo M et al. Genetic clues to the molecular basis of tobacco addiction and progress towards personalized therapy. Trends Mol Med 2001; 7: 70-6.
466. Rossing MA. Genetic influences on smoking: candidate genes. Environ Health Perspect 1998; 106: 231-8.
467. Crabbe JC. Genetic contributions to addiction. Annu Rev Psychol 2002; 53: 435-62.
468. Cami J, Farre M. Drug addiction. New Engl J Med 2003; 349: 975-86.
469. Wise RA, Bozarth MA. A psychomotor stimulant theory of addiction. Psychol Rev 1987; 94: 469-92.
470. Dani JA. Roles of dopamine signaling in nicotine addiction. Mol Psychiatry 2003; 8: 255-6.
471. Mihailescu S, Palomero-Rivero M, Meade-Huerta P et al. Effects of nicotine and mecamylamine on rat dorsal raphe neurons. Eur J Pharmacol 1998; 360: 31-6.
472. Ribeiro EB, Bettiker RL, Bogdanov M, Wurtman RJ. Effects of systemic nicotine on serotonin release in rat brain. Brain Res 1993; 621: 311-8.
473. Raunio H, Rautio A, Gullsten H, Pelkonen O. Polymorphisms of CYP2A6 and its practical consequences. Br J Clin Pharmacol 2001; 52: 357-63.
474. Pianezza ML, Sellers EM, Tyndale RF. Nicotine metabolism defect reduces smoking. Nature 1998; 393: 750.
475. Tyndale RF, Sellers EM. Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. Drug Metab Dispos 2001; 29: 548-52.
476. Sellers EM, Tyndale RF, Fernandes LC. Decreasing smoking behavior and risk through CYP2A6 inhibition. Drug Discov Today 2003; 8: 487-93.
477. Sellers EM, Kaplan HL, Tyndale RF. Inhibition of cytochrome P450 2A6 increases nicotine’s oral bioavailability and decreases smoking. Clin Pharmacol Ther 2000; 68: 35-43.
478. Tricker AR. Nicotine metabolism, human drug metabolism polymorphisms, and smoking behavior. Toxicology 2003; 183: 151-73.
479. Carter B, Long T, Cinciripini P. A meta-analytic review of the CYP2A6 genotype and smoking behavior. Nicotine Tob Res 2004; 6: 221-7.
480. London SJ, Idle JR, Daly AK, Coetzee GA. Genetic variation of CYP2A6, smoking, and risk of cancer. Lancet 1999; 353: 898-9.
481. Daly AK, Fairbrother KS, Andreassen OA et al. Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype. Pharmacogenetics 1996; 6: 319-28.
482. Lovlie R, Daly AK, Molven A et al. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett 1996; 392: 30-4.
483. Cholerton S, Boustead C, Taber H et al. CYP2D6 genotypes in cigarette smokers and non-tobacco users. Pharmacogenetics 1996; 6: 261-3.
484. Boustead C, Taber H, Idle JR, Cholerton S. CYP2D6 genotype and smoking behavior in cigarette smokers. Pharmacogenetics 1997; 7: 411-4.
485. Pontieri FE, Tanda G, Orzi F, Di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 1996; 382: 255-7.
486. Blum K, Noble EP, Sheridan PJ et al. Allelic association of human dopamine D2 receptor gene in alcoholism. J Am Med Assoc 1990; 263: 2055-60.
487. Thompson J, Thomas N, Singleton A et al. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 1997; 7: 479-84.
488. Jonsson EG, Nothen MM, Grunhage F et al. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 1999; 4: 290-6.
489. Noble EP. D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. Am J Med Genet 2003; 116B: 103-25.
490. Noble EP, St Jeor ST, Ritchie T et al. D2 dopamine receptor gene and cigarette smoking: a reward gene? Med Hypotheses 1994; 42: 257-60.
491. Comings DE, Ferry L, Bradshaw-Robinson S et al. The dopamine D2 receptor (DRD2) gene: a genetic risk factor in smoking. Pharmacogenetics 1996; 6: 73-9.
492. Anokhin AP, Todorov AA, Madden PA et al. Brain eventrelated potentials, dopamine D2 receptor gene polymorphism, and smoking. Genet Epidemiol 1999; 17 (Suppl. 1): S37-42.
493. Anokhin AP, Vedeniapin AB, Sirevaag EJ et al. The P300 brain potential is reduced in smokers. Psychopharmacology (Berl) 2000; 149: 409-13.
494. Singleton AB, Thomson JH, Morris CM et al. Lack of association between the dopamine D2 receptor gene allele DRD2*A1 and cigarette smoking in a United Kingdom population. Pharmacogenetics 1998; 8: 125-8.
495. Bierut LJ, Rice JP, Edenberg HJ et al. Family-based study of the association of the dopamine D2 receptor gene (DRD2) with habitual smoking. Am J Med Genet 2000; 90: 299-302.
496. Comings DE, Gade R, Wu S et al. Studies of the potential role of the dopamine D1 receptor gene in addictive behaviors. Mol Psychiatry 1997; 2: 44-56.
497. Shields PG, Lerman C, Audrain J et al. Dopamine D4 receptors and the risk of cigarette smoking in African-Americans and Caucasians. Cancer Epidemiol Biomarker Prev 1998; 7: 453-8.
498. Lerman C, Caporaso N, Main D et al. Depression and self-medication with nicotine: the modifying influence of the dopamine D4 receptor gene. Health Psychol 1998; 17: 56-62.
499. Gelernter J, Kranzler HR, Satel SL, Rao PA. Genetic association between dopamine transporter protein alleles and cocaine-induced paranoia. Neuropsychopharmacology 1994; 11: 195-200.
500. Lerman C, Caporaso NE, Audrain J et al. Evidence suggesting the role of specific genetic factors in cigarette smoking. Health Psychol 1999; 18: 14-20.
501. Sabol SZ, Nelson ML, Fisher C et al. A genetic association for cigarette smoking behavior. Health Psychol 1999; 18: 7-13.
502. Ling D, Niu T, Feng Y et al. Association between polymorphism of the dopamine transporter gene and early smoking onset: an interaction risk on nicotine dependence. J Hum Genet 2004; 49: 35-9.
503. Jorm AF, Henderson AS, Jacomb PA et al. Association of smoking and personality with a polymorphism of the dopamine transporter gene: results from a community survey. Am J Med Genet 2000; 96: 331-4.
504. Vandenbergh DJ, Bennett CJ, Grant MD et al. Smoking status and the human dopamine transporter variable number of tandem repeats (VNTR) polymorphism: failure to replicate and finding that never-smokers may be different. Nicotine Tob Res 2002; 4: 333-40.
505. Jonsson E, Sedvall G, Brene S et al. Dopamine-related genes and their relationships to monoamine metabolites in CSF. Biol Psychiatry 1996; 40: 1032-43.
506. Lerman C, Shields PG, Main D et al. Lack of association of tyrosine hydroxylase genetic polymorphism with cigarette smoking. Pharmacogenetics 1997; 7: 521-4.
507. Olsson C, Anney R, Forrest S et al. Association between dependent smoking and a polymorphism in the tyrosine hydroxylase gene in a prospective population-based study of adolescent health. Behav Genet 2004; 34: 85-91.
508. Checkoway H, Franklin GM, Costa-Mallen P et al. A genetic polymorphism of MAO-B modifies the association of cigarette smoking and Parkinson’s disease. Neurology 1998; 50: 1458-61.
509. Costa-Mallen P, Costa LG, Smith-Weller T et al. Genetic polymorphism of dopamine D2 receptors in Parkinson’s disease and interactions with cigarette smoking and MAO-B intron 13 polymorphism. J Neurol Neurosurg Psychiatry 2000; 69: 535-7.
510. McKinney EF, Walton RT, Yudkin P et al. Association between polymorphisms in dopamine metabolic enzymes and tobacco consumption in smokers. Pharmacogenetics 2000; 10: 483-91.
511. Kenny PJ, Markou A. Neurobiology of the nicotine withdrawal syndrome. Pharmacol Biochem Behav 2001; 70: 531-49.
512. Nielsen DA, Virkkunen M, Lappalainen J et al. A tryptophan hydroxylase gene marker for suicidality and alcoholism. Arch Gen Psychiatry 1998; 55: 593-602.
513. Sullivan PF, Jiang Y, Neale MC et al. Association of the tryptophan hydroxylase gene with smoking initiation but not progression to nicotine dependence. Am J Med Genet 2001; 105: 479-84.
514. Lerman C, Caporaso NE, Bush A et al. Tryptophan hydroxylase gene variant and smoking behavior. Am J Med Genet 2001; 105: 518-20.
515. Heils A, Teufel A, Petri S et al. Allelic variation of human serotonin transporter gene expression. J Neurochem 1996; 66: 2621-4.
516. Lerman C, Shields PG, Audrain J et al. The role of the serotonin transporter gene in cigarette smoking. Cancer Epidemiol Biomarker Prev 1998; 7: 253-5.
517. Ishikawa H, Ohtsuki T, Ishiguro H et al. Association between serotonin transporter gene polymorphism and smoking among Japanese males. Cancer Epidemiol Biomarker Prev 1999; 8: 831-3.
518. do Prado-Lima PA, Chatkin JM, Taufer M et al. Polymorphism of 5HT2A serotonin receptor gene is implicated in smoking addiction. Am J Med Genet 2004; 128B: 90-3.
519. Feng Y, Niu T, Xing H et al. A common haplotype of the nicotine acetylcholine receptor alpha 4-subunit gene is associated with vulnerability to nicotine addiction in men. Am J Hum Genet 2004; 75: 112-21.
520. Lerman C, Niaura R. Applying genetic approaches to the treatment of nicotine dependence. Oncogene 2002; 21: 7412-20.
521. Lancaster T, Stead L, Silagy C, Sowden A. Effectiveness of interventions to help people stop smoking: findings from the Cochrane Library. Br Med J 2000; 321: 355-8.
522. Ascher JA, Cole JO, Colin JN et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995; 56: 395-401.
523. Ball K, Turner R. Smoking and the heart. The basis for action. Lancet 1974; 2: 822-6.
524. Faucette SR, Hawke RL, Lecluyse EL et al. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 2000; 28: 1222-30.
525. Lerman C, Shields PG, Wileyto EP et al. Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics 2002; 12: 627-34.
526. Lerman C, Shields PG, Wileyto EP et al. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol 2003; 22: 541-8.
527. Lerman C, Wileyto EP, Patterson F et al. The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts shortterm response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J 2004; 4: 184-92.
528. Konu O, Kane JK, Barrett T et al. Region-specific transcriptional response to chronic nicotine in rat brain. Brain Res 2001; 909: 194-203.
529. Zhang S, Day IN, Ye S. Microarray analysis of nicotineinduced changes in gene expression in endothelial cells. Physiol Genomics 2001; 5: 187-92.
530. Hu D, Cao K, Peterson-Wakeman R, Wang R. Altered profile of gene expression in rat hearts induced by chronic nicotine consumption. Biochem Biophys Res Commun 2002; 297: 729-36.
531. Sullivan PF, Neale BM, van den Oord E et al. Candidate genes for nicotine dependence via linkage, epistasis, and bioinformatics. Am J Med Genet 2004; 126B: 23-36.
532. Stein EA, Pankiewicz J, Harsch HH et al. Nicotine-induced limbic cortical activation in the human brain: a functional MRI study. Am J Psychiatry 1998; 155: 1009-15.
533. Salokangas RK, Vilkman H, Ilonen T et al. High levels of dopamine activity in the basal ganglia of cigarette smokers. Am J Psychiatry 2000; 157: 632-4.
534. Swan GE, Hudmon KS, Jack LM et al. Environmental and genetic determinants of tobacco use: methodology for a multidisciplinary, longitudinal family-based investigation. Cancer Epidemiol Biomarker Prev 2003; 12: 994-1005.
535. DeMeo DL, Silverman EK. Alpha1-antitrypsin deficienc. 2: genetic aspects of alpha 1-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk. Thorax 2004; 59: 259-64.
536. Klein W, Rohde G, Arinir U et al. A promotor polymorphism in the Interleukin 11 gene is associated with chronic obstructive pulmonary disease. Electrophoresis 2004; 25: 804-8.
537. Hu RC, Xu YJ, Zhang ZX, Xie JG. [Polymorphism of interleukin-10 gene promoter and its association with susceptibility to chronic obstructive pulmonary disease in Chinese Han people]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2003; 20: 504-7.
538. Sakao S, Tatsumi K, Hashimoto T et al. Vascular endothelial growth factor and the risk of smoking-related COPD. Chest 2003; 124: 323-7.
539. Hegab AE, Sakamoto T, Uchida Y et al. CLCA1 gene polymorphisms in chronic obstructive pulmonary disease. J Med Genet 2004; 41: e27.
540. Lucey EC, Keane J, Kuang PP et al. Severity of elastaseinduced emphysema is decreased in tumor necrosis factoralpha and interleukin-1beta receptor-deficient mice. Lab Invest 2002; 82: 79-85.